TR200200588T2 - N-pirazol A2A reseptör agonistleri - Google Patents

N-pirazol A2A reseptör agonistleri

Info

Publication number
TR200200588T2
TR200200588T2 TR2002/00588T TR200200588T TR200200588T2 TR 200200588 T2 TR200200588 T2 TR 200200588T2 TR 2002/00588 T TR2002/00588 T TR 2002/00588T TR 200200588 T TR200200588 T TR 200200588T TR 200200588 T2 TR200200588 T2 TR 200200588T2
Authority
TR
Turkey
Prior art keywords
receptor agonists
pyrazole
compounds
adenosine
mammals
Prior art date
Application number
TR2002/00588T
Other languages
English (en)
Turkish (tr)
Inventor
A. Zablocki Jeffrey
O. Elzein Elfatih
P. Palle Venkata
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200200588T2 publication Critical patent/TR200200588T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
TR2002/00588T 1999-06-22 2000-06-21 N-pirazol A2A reseptör agonistleri TR200200588T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/338,185 US6403567B1 (en) 1999-06-22 1999-06-22 N-pyrazole A2A adenosine receptor agonists

Publications (1)

Publication Number Publication Date
TR200200588T2 true TR200200588T2 (tr) 2002-09-23

Family

ID=23323763

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00588T TR200200588T2 (tr) 1999-06-22 2000-06-21 N-pirazol A2A reseptör agonistleri

Country Status (27)

Country Link
US (9) US6403567B1 (US07585860-20090908-C00083.png)
EP (1) EP1189916B1 (US07585860-20090908-C00083.png)
JP (1) JP4727880B2 (US07585860-20090908-C00083.png)
KR (1) KR100463300B1 (US07585860-20090908-C00083.png)
CN (1) CN1167709C (US07585860-20090908-C00083.png)
AR (1) AR024441A1 (US07585860-20090908-C00083.png)
AT (1) ATE256141T1 (US07585860-20090908-C00083.png)
AU (1) AU760806B2 (US07585860-20090908-C00083.png)
BE (1) BE2011C004I2 (US07585860-20090908-C00083.png)
BR (1) BRPI0011856B8 (US07585860-20090908-C00083.png)
CA (1) CA2377746C (US07585860-20090908-C00083.png)
CY (1) CY2011002I1 (US07585860-20090908-C00083.png)
DE (2) DE60007127T2 (US07585860-20090908-C00083.png)
DK (1) DK1189916T3 (US07585860-20090908-C00083.png)
ES (1) ES2209974T3 (US07585860-20090908-C00083.png)
FR (1) FR11C0004I2 (US07585860-20090908-C00083.png)
HK (1) HK1044952B (US07585860-20090908-C00083.png)
IL (2) IL147198A0 (US07585860-20090908-C00083.png)
LU (1) LU91785I2 (US07585860-20090908-C00083.png)
MX (1) MXPA01013325A (US07585860-20090908-C00083.png)
NO (2) NO322457B1 (US07585860-20090908-C00083.png)
NZ (1) NZ516334A (US07585860-20090908-C00083.png)
PT (1) PT1189916E (US07585860-20090908-C00083.png)
TR (1) TR200200588T2 (US07585860-20090908-C00083.png)
TW (1) TWI230161B (US07585860-20090908-C00083.png)
WO (1) WO2000078779A2 (US07585860-20090908-C00083.png)
ZA (1) ZA200200301B (US07585860-20090908-C00083.png)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) * 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
CA2476431A1 (en) 2002-02-15 2003-08-21 Cv Therapeutics, Inc. Coating having polymerized silane derivatives for medical devices
MXPA05001123A (es) * 2002-07-29 2005-04-29 Cv Therapeutics Inc Formacion de imagenes por perfusion de miocardio mediante el uso de agonistas receptores de a2a.
US8470801B2 (en) * 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
AU2003268526A1 (en) 2002-09-09 2004-03-29 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
EP1708721B1 (en) * 2004-01-27 2013-08-07 Gilead Sciences, Inc. Myocardial perfusion imaging using adenosine receptor agonists
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
EP1802316B1 (en) * 2004-09-20 2011-11-02 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
RU2007114908A (ru) * 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
JP5203214B2 (ja) * 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
AU2007212542B2 (en) * 2006-02-03 2013-01-31 Gilead Sciences, Inc. Process for preparing an A2A-Adenosine receptor agonist and its polymorphs
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DK2013211T3 (da) 2006-04-21 2012-07-02 Novartis Ag Purinderivater til anvendelse som adenosin-A2A-receptoragonister
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DE102006020349A1 (de) 2006-04-28 2007-10-31 Mahle International Gmbh Kolbenmotor und zugehöriges Betriebsverfahren
US7691825B2 (en) * 2006-06-06 2010-04-06 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor agonists
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
WO2008055874A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
WO2008143667A1 (en) * 2007-05-17 2008-11-27 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8942112B2 (en) * 2008-02-15 2015-01-27 Cisco Technology, Inc. System and method for providing selective mobility invocation in a network environment
AU2009256009B2 (en) 2008-06-06 2014-02-06 Neurmedix, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
US7957314B2 (en) * 2008-12-12 2011-06-07 Cisco Technology, Inc. System and method for provisioning charging and policy control in a network environment
CA2784908A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INTRAOCULAR PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA) DERIVATIVES OR CPA PRODRUGS
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9215588B2 (en) 2010-04-30 2015-12-15 Cisco Technology, Inc. System and method for providing selective bearer security in a network environment
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
US8859522B2 (en) 2011-04-27 2014-10-14 Reliable Biopharmaceutical Corporation Processes for the preparation of regadenoson and a new crystalline form thereof
CZ308577B6 (cs) * 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
US20150290236A1 (en) * 2012-11-30 2015-10-15 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
ES2837751T3 (es) 2013-04-11 2021-07-01 Amri Italy S R L Formas sólidas estables de regadenoson
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
US9624258B2 (en) 2013-05-30 2017-04-18 Biophore India Pharmaceuticals Pvt. Ltd. Polymorph of regadenoson
CN104513241B (zh) * 2013-09-30 2017-02-08 浙江海正药业股份有限公司 瑞加德松新中间体及其制备方法和应用
CN104744540A (zh) * 2013-12-26 2015-07-01 上海紫源制药有限公司 一种制备瑞加德松的方法
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
TWI823085B (zh) 2017-01-13 2023-11-21 日商東菱藥品工業股份有限公司 嗜中性白血球活化調節劑
WO2019191389A1 (en) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Solid-state forms of regadenoson, their use and preparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) * 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) * 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
EP0444196B1 (en) 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE69022176T2 (de) 1989-06-20 1996-02-15 Yamasa Shoyu Kk Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
EP0644935A1 (en) 1992-06-12 1995-03-29 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
ATE218139T1 (de) * 1994-02-23 2002-06-15 Kyowa Hakko Kogyo Kk Xanthin-derivate
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
EP0983768A1 (en) 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO1999063938A2 (en) 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
DE60001969T2 (de) 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7109203B2 (en) * 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP1444233B1 (en) * 2001-11-09 2011-08-17 Gilead Palo Alto, Inc. A2b adenosine receptor antagonists
AU2002366811B2 (en) * 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2482928A1 (en) 2002-04-18 2003-10-30 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
MXPA05001123A (es) * 2002-07-29 2005-04-29 Cv Therapeutics Inc Formacion de imagenes por perfusion de miocardio mediante el uso de agonistas receptores de a2a.
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
EP1708721B1 (en) 2004-01-27 2013-08-07 Gilead Sciences, Inc. Myocardial perfusion imaging using adenosine receptor agonists
CA2583986A1 (en) * 2004-10-15 2006-04-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
RU2007114908A (ru) 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
KR20070095925A (ko) 2005-01-12 2007-10-01 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 천식이나 기관지 경련의 병력이 있는 환자에게서 심근기능장애를 검출하는 방법
AU2007212542B2 (en) * 2006-02-03 2013-01-31 Gilead Sciences, Inc. Process for preparing an A2A-Adenosine receptor agonist and its polymorphs
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
CA2663361A1 (en) 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
WO2008086096A2 (en) 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
WO2008143667A1 (en) 2007-05-17 2008-11-27 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
RU2011115815A (ru) 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии

Also Published As

Publication number Publication date
IL147198A (en) 2006-04-10
NO20016350D0 (no) 2001-12-21
ZA200200301B (en) 2003-11-26
CN1167709C (zh) 2004-09-22
EP1189916A2 (en) 2002-03-27
NO20016350L (no) 2002-02-18
BE2011C004I2 (US07585860-20090908-C00083.png) 2019-05-21
DK1189916T3 (da) 2004-03-22
US7183264B2 (en) 2007-02-27
TWI230161B (en) 2005-04-01
CY2011002I2 (el) 2012-01-25
CA2377746C (en) 2007-04-10
FR11C0004I2 (fr) 2012-03-16
BR0011856A (pt) 2004-02-10
KR20020028910A (ko) 2002-04-17
JP2003506461A (ja) 2003-02-18
US7655637B2 (en) 2010-02-02
LU91785I2 (fr) 2011-03-31
WO2000078779A3 (en) 2001-03-15
MXPA01013325A (es) 2002-07-02
US20140073596A1 (en) 2014-03-13
WO2000078779A2 (en) 2000-12-28
EP1189916B1 (en) 2003-12-10
US8278435B2 (en) 2012-10-02
US6403567B1 (en) 2002-06-11
PT1189916E (pt) 2004-03-31
ES2209974T3 (es) 2004-07-01
US20130058866A1 (en) 2013-03-07
BR0011856B1 (pt) 2014-06-17
AU760806B2 (en) 2003-05-22
US8569260B2 (en) 2013-10-29
HK1044952A1 (en) 2002-11-08
JP4727880B2 (ja) 2011-07-20
US20060052332A1 (en) 2006-03-09
BRPI0011856B8 (pt) 2021-05-25
HK1044952B (zh) 2005-02-25
DE60007127D1 (de) 2004-01-22
KR100463300B1 (ko) 2004-12-23
CN1358191A (zh) 2002-07-10
US20070203090A1 (en) 2007-08-30
DE122011000010I1 (de) 2011-06-16
US7144872B2 (en) 2006-12-05
CA2377746A1 (en) 2000-12-28
AU7132400A (en) 2001-01-09
NO2011002I1 (no) 2011-03-07
US20100160620A1 (en) 2010-06-24
FR11C0004I1 (fr) 2011-03-11
AR024441A1 (es) 2002-10-02
ATE256141T1 (de) 2003-12-15
US6642210B1 (en) 2003-11-04
NO2011002I2 (no) 2012-10-22
NO322457B1 (no) 2006-10-09
NZ516334A (en) 2004-05-28
CY2011002I1 (el) 2012-01-25
US20110144320A1 (en) 2011-06-16
DE60007127T2 (de) 2004-09-16
IL147198A0 (en) 2002-08-14
US9045519B2 (en) 2015-06-02
US20040038928A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
TR200201001T2 (tr) Pürin türevleri
TR200103752T2 (tr) Propargil fenil eter A2A reseptörü agonistleri.
TR200200985T2 (tr) Pürin türevleri
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
YU81100A (sh) Derivati 2-(purin-9-il)tetrahidrofuran-3,4 diola
MX9206409A (es) 2-etil 1h-imidazo[4,5-c]quinolin-4-aminas
DE3752123D1 (de) Derivate des physiologisch aktiven mittels k-252
DE3883374T2 (de) Acylatiertes uridin und cytidin und deren verwendungen.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
TR200103607T2 (tr) Pürin Türevleri
TR200002980T2 (tr) İnhibe edici etkiye sahip ikame edilmiş indolinonlar
NO20032759D0 (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som SDSI/CHK2-inhibitorerog adjuvanter ved kjemoterapi eller strålingsterapi ved behandlingav kreft
MY129445A (en) Compositions for treating inflammatory response
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
NZ516336A (en) Thiophene A2A receptor agonists
IS2143B (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR200103237T2 (tr) İmidazodiazepin türevi
DK1359943T3 (da) Biotinderivater og deres konjugater med chelateringsmidler
UY26498A1 (es) Pirroles sustituidos